Observational studyOncology research2026

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Luigi Coltelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.